Dr BSc - Mesoblast Scientific Officer
| MESO Stock | USD 17.58 0.46 2.55% |
Executive
Dr BSc is Scientific Officer of Mesoblast
| Age | 66 |
| Address | 55 Collins Street, Melbourne, VIC, Australia, 3000 |
| Phone | 61 3 9639 6036 |
| Web | https://www.mesoblast.com |
Mesoblast Management Efficiency
The company has return on total asset (ROA) of (0.0541) % which means that it has lost $0.0541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1791) %, meaning that it created substantial loss on money invested by shareholders. Mesoblast's management efficiency ratios could be used to measure how well Mesoblast manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of January 2025, Return On Tangible Assets is likely to drop to -1.14. In addition to that, Return On Capital Employed is likely to grow to -0.13. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 23rd of January 2025, Total Current Assets is likely to grow to about 116.5 M, while Total Assets are likely to drop about 583.1 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gayle Gironda | Inozyme Pharma | N/A | |
| Roman Necina | Hookipa Pharma | 57 | |
| Robyn Hunter | Fortress Biotech | 62 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| DO Sr | Larimar Therapeutics | 63 | |
| Kevin Guthrie | Eton Pharmaceuticals | N/A | |
| Paul Little | Eledon Pharmaceuticals | 60 | |
| David Krempa | Eton Pharmaceuticals | 36 | |
| James Taylor | Achilles Therapeutics PLC | 63 | |
| Jiang JD | Connect Biopharma Holdings | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Debra SPHR | Mustang Bio | N/A | |
| Dr MS | Fennec Pharmaceuticals | N/A | |
| Joe Bonaccorso | Verrica Pharmaceuticals | 60 | |
| James Murphy | Mustang Bio | 67 | |
| Robyn Hunter | Mustang Bio | 63 | |
| Moses Makunje | Nuvation Bio | 45 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Robyn Hunter | Fortress Biotech Pref | 61 | |
| Daniel Courtney | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 |
Mesoblast Leadership Team
Elected by the shareholders, the Mesoblast's board of directors comprises two types of representatives: Mesoblast inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mesoblast. The board's role is to monitor Mesoblast's management team and ensure that shareholders' interests are well served. Mesoblast's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mesoblast's outside directors are responsible for providing unbiased perspectives on the board's policies.
| LLB BCom, Joint Secretary | ||
| Justin BS, Head Manufacturing | ||
| Marcelo Santoro, Chief Officer | ||
| Roger BA, Head Disorders | ||
| Fiona See, Senior Research | ||
| MS MBA, Chief Officer | ||
| BSc LLB, Gen Exec | ||
| FACP FACRA, CEO, Founder | ||
| Eric MD, Chief Director | ||
| Andrew BCom, Interim Officer | ||
| Paul BPHARM, Joint Secretary | ||
| MBA MS, Head Partnering | ||
| Dr BSc, Scientific Officer |
Mesoblast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mesoblast a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 2.14 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 1.38 % | ||||
| Number Of Shares Shorted | 1.8 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 4.34 X |
Pair Trading with Mesoblast
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.Moving against Mesoblast Stock
| 0.78 | PDSB | PDS Biotechnology Corp | PairCorr |
| 0.76 | KRYS | Krystal Biotech | PairCorr |
| 0.75 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.64 | INZY | Inozyme Pharma | PairCorr |
| 0.59 | MREO | Mereo BioPharma Group | PairCorr |
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.